Transparency Life Sciences

Envisioning the site of the future

Monday, May 1, 2017

The drug development world has been notoriously slow to adopt change, but industry leaders and visionaries expect the clinical research enterprise to change dramatically.
Integration of healthcare data, the power of data and analytics, a rapid move toward more targeted therapies and customized treatments, along with the desire for a lower cost R&D model are among the forces driving transformation in the way the research environment will function in the future.

[Read More]

Advisory boards amplify patients’ voices

Tuesday, September 15, 2015

A strong and growing desire to solicit feedback directly from patients, ex­perienced participants and their sup­port network is prompting many sponsors and CROs to assess, plan and implement patient advisory panels.

[Read More]

Transparency Life Sciences assesses feasibility of decentralized patient data collection

Friday, August 7, 2015

Transparency Life Sciences, a clinical-stage drug development company based on open innovation, has enrolled its first patient in a new ulcerative colitis trial designed to assess the feasibility of replacing most conventional patient site visits with data collected using a combination of decentralized methods, including digital measurements, telemonitoring, remote video visits with clinical trial staff and blood collections by visiting nurses. In addition, the study is the first to allow key clinical endpoint assessments to be made by the subjects’ own gastroenterologists, rather than via designated sub-investigators affiliated with the trial.

[Read More]

Transparency Life Sciences, Mount Sinai partner

Wednesday, November 20, 2013

Transparency Life Sciences (TLS), a drug development company based on open innovation, is collaborating with Dr. Matthew Galsky, associate professor of medicine, division of hematology/oncology at the Icahn School of Medicine at Mount Sinai, to design and conduct a pilot trial assessing metformin as a potential treatment for prostate cancer. Metformin is a widely prescribed diabetes drug that has shown promising activity against prostate and other cancers in preclinical and clinical studies.

[Read More]